Laverock Therapeutics has been confirmed as the latest tenant to take space at London BioScience Innovation Centre at the Apex in King’s Cross. N1.
The gene silencing technology company has signed a five-year lease for 4,133 sq ft of fully fitted lab and office space.
Estates Gazette revealed Laverock was among the early movers to the space late last year. It will join novel vaccine developer Baseimmune, which will occupy 3,350 sq ft of lab and office space, also on a five-year lease.
London BioScience Innovation Centre spans 37,127 sq ft and sits within one of five mixed-use buildings in the wider 600,000 sq ft Tribeca development, which is being delivered by Reef Group and BlackRock Alternatives.
Both Baseimmune and Laverock are understood to be paying a price in line with current market headline rents in the King’s Cross area for lab space. Tribeca is quoted at around £130 per sq ft.
Tom Payne, chief operating officer at Laverock, said: “As part of the Knowledge Quarter, the Tribeca development provides the best of all worlds – with great transport links, an aspirational work environment, and close proximity to world-class academic and translational centres, making it the leading hub for life sciences companies in Europe.”
Image © LBIC
Send feedback to Evelina Grecenko
